10Dec/13

Latest Data Further Support Ibrutinib's Efficacy in CLL – OncLive


OncLive

Latest Data Further Support Ibrutinib’s Efficacy in CLL
OncLive
Combining ibrutinib with the chemoimmunotherapy regimen of bendamustine (Treanda) plus rituximab (Rituxan) demonstrated a high level of activity and was tolerable for patients with relapsed or refractory CLL.1 Presenting the final results of the 30
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell MalignanciesMarketWatch

all 34 news articles »

10Dec/13

Kelly Thomas Trial update: Doctor testifies Thomas was in 'critical' condition … – 89.3 KPCC


89.3 KPCC

Kelly Thomas Trial update: Doctor testifies Thomas was in ‘critical’ condition
89.3 KPCC
Rackauckas asked Lekawa what caused Thomas’ death. Lekawa: “His heart stopped in the field and a lack of oxygen to the brain caused irreversible brain injury and brain death.” On further questioning from Rackauckas, Lekawa connected actions during the 

and more »

10Dec/13

Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in … – 4-traders (press release)

Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in
4-traders (press release)
In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an 

and more »

10Dec/13

Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH – Business Wire (press release)

Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Business Wire (press release)
In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an 

and more »